Stocks · News reference
Onconetix, Inc. has issued an additional $500,000 advance to Realbotix LLC under their existing bridge financing facility, bringing the total outstanding principal to $3,000,000.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Onco-Innovations Limited has entered into a termination agreement with Sorbie Bornholm LP and Sorbie Investments LLP to end their performance-based funding arrangement.
The European Commission has formally approved a Type II variation for Oncopeptides' Pepaxti, expanding its use to adult patients with multiple myeloma who have received at least two prior lines of therapy.
Filed: 2026-11-09 AccNo: 0001213900-26-117223 Size: 211 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Onconetix, Inc. entered into a first amendment to its stock-for-stock merger agreement with Realbotix, as disclosed in an SEC filing dated November 4, 2026.
Oncopeptides AB announced its third-quarter 2026 financial results, highlighting a 41% year-over-year increase in sales and a 98% gross margin for the first nine months of the year.